NDLI: Comparison of charges and resource use associated with saxagliptin and sitagliptin

Content Provider	Springer Nature : BioMed Central
Author	Vaidya, Varun Adhikari, Keyuri Sheehan, Jack Kalsekar, Iftekhar
Abstract	Objectives Saxagliptin and sitagliptin are two commonly used dipeptidyl peptidase-4 (DPP-4) inhibitors. Little is known about their comparative effectiveness in the real world, particularly their impact on cost and resources use. The objective of this study was to analyze charges and resource use associated with saxagliptin and sitagliptin to understand the impact of these DPP-4 inhibitor treatment options in a real-world setting. Methods This was a retrospective, new-user study approved by the Institutional Review Board at the University of Toledo. Data were collected from a US insurance claims dataset (OptumInsight) for patients newly initiating treatment with saxagliptin or sitagliptin between January 1, 2010 and December 31, 2011. ICD-9 code 250 was used to identify patients with T2D. Overall and diabetes-related medical and pharmacy charges were observed. Inpatient hospitalizations were also compared. Propensity score matching was used to balance the cohorts of patients prescribed saxagliptin and sitagliptin. Appropriate univariate statistical tests were applied to the propensity-matched sample to examine differences in resource utilization outcomes. Statistical significance was evaluated at P < 0.05. Result After the propensity score matching, each cohort included 7711 patients. Saxagliptin treatment was associated with lower overall charges ($13,292 vs $14,032; P = 0.0023) and overall medical charges ($9,540 vs $10,296; P = 0.0024) during the 6-month follow-up period compared with sitagliptin treatment. No significant differences were observed in the overall pharmacy charges ($3,751 vs $3,753; P = 0.6937) and the diabetes-related charges ($5,141 vs $5,232; P = 0.2957). All-cause and diabetes-related inpatient hospitalization rates were significantly lower with saxagliptin treatment (p = 0.0001 and p = 0.0019, respectively). All-caused inpatient charges were also significantly lower with saxagliptin ($2,917.26 vs $3445.89; P < 0.0001). Conclusion Compared with patients initiating sitagliptin treatment, patients initiating saxagliptin treatment reported lower overall and medical charges and lower overall and diabetes-related hospitalization rates. These findings may aid payers in managing patients with T2D.
Related Links	https://healtheconomicsreview.biomedcentral.com/counter/pdf/10.1186/s13561-016-0104-8.pdf
Ending Page	7
Page Count	7
Starting Page	1
File Format	HTM / HTML
ISSN	21911991
DOI	10.1186/s13561-016-0104-8
Journal	Health Economics Review
Issue Number	1
Volume Number	6
Language	English
Publisher	BioMed Central
Publisher Date	2016-07-07
Access Restriction	Open
Subject Keyword	Public Health Health Economics Public Economics Pharmacoeconomics and Health Outcomes Health Care Management Health Services Research Propensity Score Sitagliptin Propensity Score Match DPP4 Inhibitor Saxagliptin
Content Type	Text
Resource Type	Article
Subject	Health Policy
Journal Impact Factor	2.7/2023
5-Year Journal Impact Factor	2.8/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina

Selective admission into stroke unit and patient outcomes: a tale of four cities

Health Economics Review

Kidney transplant cases in US: study of determinants of variance in hospital charges and inpatient care

Social costs associated with fibromyalgia in Spain

Greetings from the Editors

Socioeconomic determinants of use of reproductive health services in Ghana

Food environment and childhood obesity: the effect of dollar stores

Which indicator should be used? A comparison between the incidence and intensity of catastrophic health expenditure: using difference-in-difference analysis

Comparison of charges and resource use associated with saxagliptin and sitagliptin

Similar Documents

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina

Selective admission into stroke unit and patient outcomes: a tale of four cities

Health Economics Review

Kidney transplant cases in US: study of determinants of variance in hospital charges and inpatient care

Social costs associated with fibromyalgia in Spain

Greetings from the Editors

Socioeconomic determinants of use of reproductive health services in Ghana

Food environment and childhood obesity: the effect of dollar stores

Which indicator should be used? A comparison between the incidence and intensity of catastrophic health expenditure: using difference-in-difference analysis

Comparison of charges and resource use associated with saxagliptin and sitagliptin